Zimmer Biomet Holdings ((ZBH)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Zimmer Biomet Holdings is conducting a study titled ‘Post-Market Clinical Follow-Up Study to Provide Safety, Performance and Clinical Benefits Data of the XtraFix® Small External Fixation System.’ The primary aim is to confirm the safety and performance of the XtraFix® system in treating long bone fractures, with a focus on fracture healing and the incidence of complications.
The intervention being tested is the XtraFix® Small External Fixation System, designed to aid in the healing of wrist and proximal humerus fractures by providing external support to the bone.
This observational study follows a cohort model, where data is collected retrospectively. It is non-randomized and non-controlled, focusing on real-world application and outcomes.
The study began on May 22, 2023, and is currently recruiting participants. The last update was submitted on November 4, 2024. These dates are crucial for tracking the study’s progress and ensuring timely data collection and analysis.
For investors, this study could influence Zimmer Biomet’s market position by validating the efficacy of the XtraFix® system, potentially boosting investor confidence and stock performance. The outcome may also impact the competitive landscape in the orthopedic device industry.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.